An Early Phase 1 interventional study of Metformin Hydrochloride and placebo in Gestational Diabetes, sponsored by Anna Stanhewicz, PhD. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Anna Stanhewicz, PhD · Early Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing metformin in Diabetes, Gestational — 4 open to participants now, 5 under way, none of them phase 3. Metformin · Diabetes, Gestational.
Among the 39 studies testing metformin in Diabetes, Gestational, this one is the 34th largest by planned enrollment, is one of 3 that started in 2024, is the only one in phase 1, and was the 35th registered.
878 studies on the registry are indexed under Diabetes, Gestational; 196 are open to participants now.
Browse Diabetes, Gestational studies →4 of the 39 studies testing metformin in Diabetes, Gestational are open now, in 1 country. Recruiting first, the newest first:
University of Virginia · Sites in United States
Ages 18–50 · Women only
Ohio State University · Sites in United States
Ages 18+ · Women only
Assiut University
Ages 18–40 · Women only
By country, each count listing its studies:
Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 132 Diabetes, Gestational studies recruiting now, 60 (45%) set no upper age limit and 70 (53%) stop at 75 or younger; 12 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 45 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 16 · Phase 4 13
First in 2002; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 110 across 563 interventional studies indexed under Diabetes, Gestational.
Median enrollment 112 across the 39 interventional studies. Of the 23 that completed or were terminated, 7 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 39 has an industry lead sponsor. The 10 most frequent:
Anna Stanhewicz, PhD is the lead sponsor of 15 studies on the registry; 8 are open to participants now.
Anna Stanhewicz, PhD has 5 studies filed under Diabetes, Gestational — fewer than ten, so there is no comparison to draw.
1 of the studies testing metformin in Diabetes, Gestational that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06948825George Washington UniversityEffectiveness Study of a Lifestyle Intervention Versus Metformin in Mothers With Recent Gestational Diabetes | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 39 studies testing metformin in Diabetes, Gestational, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this investigation is to examine the mechanisms mediating vascular dysfunction in women who have had gestational diabetes and how metformin may be a valuable treatment tool to improve microvascular function in these women before the onset of disease.
Women with a history of gestational diabetes mellitus (GDM) are at a 2-fold greater risk for the development of overt cardiovascular disease (CVD) following the effected pregnancy. While subsequent development of type II diabetes elevates this risk, prior GDM is an independent risk factor for CVD morbidity, particularly within the first decade postpartum. GDM is associated with impaired endothelial function during pregnancy and decrements in macro- and microvascular function persist postpartum, despite the remission of insulin resistance following delivery. Collectively, while the association between GDM and elevated lifetime CVD risk is clear, and available evidence demonstrates a link between GDM and vascular dysfunction in the decade following pregnancy, the mechanisms mediating this persistent dysfunction remain unexamined.
The purpose of this investigation is to examine the mechanisms mediating vascular dysfunction in women who have had gestational diabetes and how metformin may be a valuable treatment tool to improve microvascular function in these women before the onset of disease. This study will give rise to a new line of research that will center around the goal of improving lifetime cardiovascular outcomes in women with a history of GDM.
In this study, the investigators use the blood vessels in the skin as a representative vascular bed for examining mechanisms of microvascular dysfunction in humans. Using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) they examine the blood vessels in a dime-sized area of the skin in women who have had GDM. Local heating of the skin at the microdialysis sites is used to explore differences in mechanisms governing microvascular control. As a compliment to these measurements, the investigators also draw blood from the subjects and isolate the inflammatory cells.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Metformin Hydrochloride
Other: placebo
12 weeks: 850mg metformin once daily for first 7 days then twice daily for the remaining 11 weeks.
12 weeks: placebo tablet once daily for the first 7 days then twice daily for the remaining 11 weeks.
blood flow response to acetylcholine
cutaneous microvascular dilation (cutaneous conductance ; %max) response to acetylcholine
Time frame: baseline
blood flow response to acetylcholine
cutaneous microvascular dilation (cutaneous conductance ; %max) response to acetylcholine
Time frame: 1 week of treatment
blood flow response to acetylcholine
cutaneous microvascular dilation (cutaneous conductance ; %max) response to acetylcholine
Time frame: 6 weeks of treatment
blood flow response to acetylcholine
cutaneous microvascular dilation (cutaneous conductance ; %max) response to acetylcholine
Time frame: 12 weeks of treatment
blood flow response to insulin
cutaneous microvascular dilation (cutaneous conductance ; %max) response to insulin
Time frame: baseline
blood flow response to insulin
cutaneous microvascular dilation (cutaneous conductance ; %max) response to insulin
Time frame: 1 week of treatment
blood flow response to insulin
cutaneous microvascular dilation (cutaneous conductance ; %max) response to insulin
Time frame: 6 weeks of treatment
blood flow response to insulin
cutaneous microvascular dilation (cutaneous conductance ; %max) response to insulin
Time frame: 12 weeks of treatment
Percentage of nitric oxide-dependent dilation
NO-dependent (%) cutaneous microvascular dilation response to acetylcholine
Time frame: baseline
Percentage nitric oxide-dependent dilation
NO-dependent (%) cutaneous microvascular dilation response to acetylcholine
Time frame: 1 week of treatment
Percentage of nitric oxide-dependent dilation
NO-dependent (%) cutaneous microvascular dilation response to acetylcholine
Time frame: 6 weeks of treatment
Percentage of nitric oxide-dependent dilation
NO-dependent (%) cutaneous microvascular dilation response to acetylcholine
Time frame: 12 weeks of treatment
Plan to share: Yes — Findings from the primary studies will be published and submitted to PubMed Central in compliance with the NIH public access policy. These findings will also be made public through the clinicaltrial.gov record. The final data set will be stripped of any identifying data prior to release for sharing. We will make the data and any associated documentation available to users only under a data-sharing agreement that provides for: 1) a commitment to using the data only for research purposes and not to identify any one individual participant; 2) a commitment to securing the data using appropriate computer technology; and 3) a commitment to destroying or returning the data after all analyses are completed.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code
No publications or documents are linked to this record.
Started Sep 2024 (actual). Primary completion is estimated for Dec 2027, 39 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metformin
Anna Stanhewicz, PhD